Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Kimberly Velthuis, Naomi T. Jessurun, Thi D.M. Nguyen, Joep Scholl, Jurriaan R.G. Jansen, Jette A. van Lint, Leanne J. Kosse, Peter M. ten Klooster & Harald E. Vonkeman. (2023) First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert Opinion on Drug Safety 22:6, pages 485-492.
Read now
Read now
Yoshiya Tanaka, Tsuneyo Mimori, Hisashi Yamanaka, Naomi Sunaga, Kazuo Morita, Junko Kimura & Tsutomu Takeuchi. (2020) Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. Modern Rheumatology 30:3, pages 424-433.
Read now
Read now
Ying Huang, Weiji Lin, Zhe Chen, Yu Wang, Yao Huang & Shenghao Tu. (2019) Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?. Drug Design, Development and Therapy 13, pages 2111-2125.
Read now
Read now
Yoshiki Nagai, Naoto Yokogawa, Kota Shimada & Shoji Sugii. (2019) Comparison of the clinical characteristics and severity of community-acquired pneumonia between patients with rheumatoid arthritis treated with tocilizumab and those treated with TNF inhibitor. Modern Rheumatology 29:5, pages 782-787.
Read now
Read now
Yoshiya Tanaka, Tsuneyo Mimori, Hisashi Yamanaka, Ryo Nakajima, Kazuo Morita, Junko Kimura & Tsutomu Takeuchi. (2019) Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. Modern Rheumatology 29:4, pages 572-580.
Read now
Read now
Kazuichi Maruyama. (2019) Current standardized therapeutic approach for uveitis in Japan. Immunological Medicine 42:3, pages 124-134.
Read now
Read now
Takahiro Nunokawa, Naoto Yokogawa, Kota Shimada & Shoji Sugii. (2019) Effect of sulfasalazine use on the presence of Pneumocystis organisms in the lung among patients with rheumatoid arthritis: A test-negative design case–control study with PCR tests. Modern Rheumatology 29:3, pages 436-440.
Read now
Read now
Yoshiya Tanaka, Tatsuya Atsumi, Koichi Amano, Masayoshi Harigai, Taeko Ishii, Osamu Kawaguchi, Terence P. Rooney, Naotsugu Akashi & Tsutomu Takeuchi. (2018) Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. Modern Rheumatology 28:4, pages 583-591.
Read now
Read now
Yoko Shimizu, Eiichi Tanaka, Eisuke Inoue, Kumi Shidara, Naoki Sugimoto, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2018) Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort. Modern Rheumatology 28:3, pages 461-467.
Read now
Read now
Masako Tsukamoto, Hideto Kameda, Tatsuhiro Ohshige, Yuko Kaneko, Keiko Yoshimoto, Katsuya Suzuki & Tsutomu Takeuchi. (2017) Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis. Modern Rheumatology 27:5, pages 778-781.
Read now
Read now
Juan Chen, Shuhong Chi, Feng Li, Jiali Yang, William C. Cho & Xiaoming Liu. (2017) Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies. Expert Opinion on Biological Therapy 17:3, pages 265-283.
Read now
Read now
Keiko Funahashi, Satoru Koyano, Hirotoshi Echizen & Tsukasa Matsubara. (2017) Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis. Modern Rheumatology 27:2, pages 271-277.
Read now
Read now
Hideki Nakamura, Naoki Iwamoto, Takehiro Matsumoto & Atsushi Kawakami. (2016) An effective medical partnership in Nagasaki, Japan for patients with rheumatoid arthritis. Modern Rheumatology 26:6, pages 878-884.
Read now
Read now
Masayoshi Harigai, Naoki Ishiguro, Shigeko Inokuma, Tsuneyo Mimori, Junnosuke Ryu, Syuji Takei, Tsutomu Takeuchi, Yoshiya Tanaka, Yoshinari Takasaki, Hisashi Yamanaka, Masahiko Watanabe, Hiroshi Tamada & Takao Koike. (2016) Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Modern Rheumatology 26:4, pages 491-498.
Read now
Read now
Masato Yagita, Toshiaki Hamano, Saori Hatachi & Masaaki Fujita. (2016) Peripheral neuropathies during biologic therapies. Modern Rheumatology 26:2, pages 288-293.
Read now
Read now
Hisashi Yamanaka, Masayoshi Harigai, Naoki Ishiguro, Shigeko Inokuma, Syuji Takei, Tsutomu Takeuchi, Yoshiya Tanaka, Haruko Suzuki, Yasuhiko Shinmura & Takao Koike. (2015) Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan. Modern Rheumatology 25:4, pages 495-502.
Read now
Read now
Eri Sato, Eiichi Tanaka, Moeko Ochiai, Yoko Shimizu, Akiko Kobayashi, Kumi Shidara, Daisuke Hoshi, Naoki Sugimoto, Eisuke Inoue, Yohei Seto, Ayako Nakajima, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka. (2015) Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Modern Rheumatology 25:3, pages 350-357.
Read now
Read now
Tsutomu Takeuchi, Nobuyuki Miyasaka, Shinichi Kawai, Naonobu Sugiyama, Hirotoshi Yuasa, Noriaki Yamashita, Noriko Sugiyama, Lorin Craig Wagerle, Bonnie Vlahos & Joseph Wajdula. (2015) Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials. Modern Rheumatology 25:2, pages 173-186.
Read now
Read now
Takao Koike, Masayoshi Harigai, Naoki Ishiguro, Shigeko Inokuma, Syuji Takei, Tsutomu Takeuchi, Hisashi Yamanaka, Shigenori Haruna, Naoko Ushida, Katsuyoshi Kawana & Yoshiya Tanaka. (2014) Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. Modern Rheumatology 24:3, pages 390-398.
Read now
Read now
Tsutomu Takeuchi, Shinichi Kawai, Kazuhiko Yamamoto, Masayoshi Harigai, Kota Ishida & Nobuyuki Miyasaka. (2014) Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. Modern Rheumatology 24:1, pages 8-16.
Read now
Read now
Fabiola Atzeni, Luigi Boiardi, Salvatore Sallì, Maurizio Benucci & Piercarlo Sarzi-Puttini. (2013) Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Review of Clinical Immunology 9:7, pages 649-657.
Read now
Read now
Articles from other publishers (47)
Samer Imad Mohammed, Ali Lateef Jasim, Mohammad Yawuz Jamal & Saad Abdulrahman Hussain. (2023) Factors Influencing Adalimumab Treatment Response in Patients with Rheumatoid Arthritis: The Future of Clinical Expertise. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) 5, pages 192-204.
Crossref
Crossref
Michiaki Takagi, Tatsuya Atsumi, Hiroaki Matsuno, Naoto Tamura, Takao Fujii, Nami Okamoto, Nobunori Takahashi, Atsuo Nakajima, Ayako Nakajima, Naoto Tsujimoto, Atsushi Nishikawa, Taeko Ishii, Tsutomu Takeuchi & Masataka Kuwana. (2023) Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Modern Rheumatology 33:4, pages 647-656.
Crossref
Crossref
Iulia-Tania Andronache, Victoria-Cristina Şuţa, Maria Şuţa, Sabina-Livia Ciocodei, Liliana Vladareanu, Alina Doina Nicoara & Oana Cristina Arghir. (2023) Better Safe than Sorry: Rheumatoid Arthritis, Interstitial Lung Disease, and Medication—A Narrative Review. Biomedicines 11:6, pages 1755.
Crossref
Crossref
Hideyuki Shiba, Takuya Kotani, Koji Nagai, Kenichiro Hata, Wataru Yamamoto, Ayaka Yoshikawa, Yumiko Wada, Yuri Hiramatsu, Hidehiko Makino, Yo Ueda, Akira Onishi, Koichi Murata, Hideki Amuro, Yonsu Son, Ryota Hara, Toru Hirano, Kosuke Ebina, Masaki Katayama, Motomu Hashimoto & Tohru Takeuchi. (2023) Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study. International Journal of Molecular Sciences 24:8, pages 7399.
Crossref
Crossref
Hideto Kameda, Keiichiro Nishida, Toshihiro Nanki, Akira Watanabe, Yukiya Oshima & Shigeki Momohara. (2023) Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study. Modern Rheumatology 33:3, pages 460-471.
Crossref
Crossref
Masayoshi Harigai, Takao Fujii, Ryoko Sakai, Ataru Igarashi, Ayako Shoji, Hiroko Yamaguchi, Katsuhiko Iwasaki, Misako Makishima, Amika Yoshida, Norihiro Okada, Katsuhisa Yamashita & Yutaka Kawahito. (2023) Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database. Modern Rheumatology.
Crossref
Crossref
Takahiro Nunokawa, Naofumi Chinen, Kota Shimada, Makiko Kimura, Mutsuto Tateishi, Fang Yi Chen, Keigo Setoguchi & Makoto Sugihara. (2023) Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study. Journal of Infection and Chemotherapy 29:2, pages 193-197.
Crossref
Crossref
Ryan Ha, Yoav Keynan & Zulma Vanessa Rueda. (2022) Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Crossref
Kenichi Namba, Toshikatsu Kaburaki, Hidekazu Tsuruga, Yohei Ogawa, Eri Iwashita & Hiroshi Goto. (2022) Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients. Ophthalmology and Therapy 11:3, pages 1147-1161.
Crossref
Crossref
Shin-ichiro Ohmura, Yoichiro Homma, Takayuki Masui & Toshiaki Miyamoto. (2022) Factors Associated with <i>Pneumocystis jirovecii</i> Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study. Internal Medicine 61:7, pages 997-1006.
Crossref
Crossref
Ashish Sharma & Ashok Kumar. 2022. Handbook of Biologics for Rheumatological Disorders. Handbook of Biologics for Rheumatological Disorders
141
146
.
Moayad Al Sona, Hassan Al Battah, Amr Salama & Richard Alweis. (2021) Fatal Pneumocystis jirovecii Pneumonia in a Patient on Adalimumab: A Case Report. American Journal of Therapeutics 28:4, pages e497-e498.
Crossref
Crossref
Arisa Iba, Jun Tomio, Hayato Yamana, Takehiro Sugiyama, Takashi Yoshiyama & Yasuki Kobayashi. (2020) Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune‐mediated inflammatory diseases: A longitudinal population‐based analysis using claims data. Health Science Reports 3:4.
Crossref
Crossref
Andreina Manfredi, Giulia Cassone, Federica Furini, Elisa Gremese, Vincenzo Venerito, Fabiola Atzeni, Eugenio Arrigoni, Giovanni Della Casa, Stefania Cerri, Marcello Govoni, Luca Petricca, Florenzo Iannone, Carlo Salvarani & Marco Sebastiani. (2020) Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Internal Medicine Journal 50:9, pages 1085-1090.
Crossref
Crossref
Giulia Cassone, Andreina Manfredi, Caterina Vacchi, Fabrizio Luppi, Francesca Coppi, Carlo Salvarani & Marco Sebastiani. (2020) Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. Journal of Clinical Medicine 9:4, pages 1082.
Crossref
Crossref
Spinello Antinori & Andrea Giacomelli. 2020. Infections in Systemic Autoimmune Diseases: Risk Factors and Management. Infections in Systemic Autoimmune Diseases: Risk Factors and Management
13
48
.
Natália Sarzi Sartori, Paulo Picon, Afonso Papke, Jeruza Lavanholi Neyeloff & Rafael Mendonça da Silva Chakr. (2019) A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment. PLOS ONE 14:12, pages e0224963.
Crossref
Crossref
Takuya Matsumoto, Shingo Iwano, Nobunori Takahashi, Shuji Asai, Tatsuo Watanabe, Nobuyuki Asai, Yasumori Sobue, Satoru Ito, Naoki Ishiguro & Toshihisa Kojima. (2018) Association between chest computed tomography findings and respiratory adverse events in rheumatoid arthritis patients undergoing long‐term biological therapy. International Journal of Rheumatic Diseases 22:4, pages 626-635.
Crossref
Crossref
Theodoros Karampitsakos, Argyro Vraka, Demosthenes Bouros, Stamatis-Nick Liossis & Argyris Tzouvelekis. (2019) Biologic Treatments in Interstitial Lung Diseases. Frontiers in Medicine 6.
Crossref
Crossref
Tetsuya Hanaka, Takashi Kido, Hiroshi Ishimoto, Keishi Oda, Shingo Noguchi, Aya Nawata, Shingo Nakayamada, Noriho Sakamoto, Yoshiya Tanaka, Kazuhiro Yatera & Hiroshi Mukae. (2019) Radiological patterns of pulmonary involvement may predict treatment response in rheumatoid arthritis: A retrospective study. Respiratory Investigation 57:2, pages 172-182.
Crossref
Crossref
Takahiro Nunokawa, Naoto Yokogawa, Kota Shimada, Shoji Sugii, Jinju Nishino, Masahiko Gosho, Yukiko Wagatsuma & Shigeto Tohma. (2019) Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: A nested case-control study. Seminars in Arthritis and Rheumatism 48:4, pages 573-578.
Crossref
Crossref
Kee Fong Phang, Gim Gee Teng, Lynette L.S. Teo, Ju Ee Seet, Chia Meng Teoh & Felicia S.W. Teo. (2018) A 67-Year-Old Man With Psoriatic Arthritis and New-Onset Dyspnea. Chest 154:5, pages e127-e134.
Crossref
Crossref
Sarah Skeoch, Nicholas Weatherley, Andrew Swift, Alexander Oldroyd, Christopher Johns, Conal Hayton, Alessandro Giollo, James Wild, John Waterton, Maya Buch, Kim Linton, Ian Bruce, Colm Leonard, Stephen Bianchi & Nazia Chaudhuri. (2018) Drug-Induced Interstitial Lung Disease: A Systematic Review. Journal of Clinical Medicine 7:10, pages 356.
Crossref
Crossref
Ryoko Sakai, Shoko Kasai, Fumio Hirano, Sayoko Harada, Mari Kihara, Waka Yokoyama, Michi Tsutsumino, Kenji Nagasaka, Ryuji Koike, Hisashi Yamanaka, Nobuyuki Miyasaka & Masayoshi Harigai. (2018) No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. International Journal of Rheumatic Diseases 21:9, pages 1670-1677.
Crossref
Crossref
J.W. Baddley, F. Cantini, D. Goletti, J.J. Gómez-Reino, E. Mylonakis, R. San-Juan, M. Fernández-Ruiz & J. Torre-Cisneros. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clinical Microbiology and Infection 24, pages S10-S20.
Crossref
Crossref
Sadatomo Tasaka. 2018. Lung Disease Associated with Rheumatoid Arthritis. Lung Disease Associated with Rheumatoid Arthritis
187
199
.
Yutaka Tsuchiya & Hironori Sagara. 2018. Lung Disease Associated with Rheumatoid Arthritis. Lung Disease Associated with Rheumatoid Arthritis
151
164
.
Jun Tomio, Hayato Yamana, Hiroki Matsui, Hiroyuki Yamashita, Takashi Yoshiyama & Hideo Yasunaga. (2017) Tuberculosis screening prior to anti‐tumor necrosis factor therapy among patients with immune‐mediated inflammatory diseases in Japan: a longitudinal study using a large‐scale health insurance claims database. International Journal of Rheumatic Diseases 20:11, pages 1674-1683.
Crossref
Crossref
Hitoshi Tokuda, Masayoshi Harigai, Hideto Kameda, Kazunori Tomono, Noboru Takayanagi, Akira Watanabe, Sadatomo Tasaka, Takafumi Suda, Kazuhiro Tateda & Junichi Kadota. (2017) Consensus statements for medical practice: Biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society]. Respiratory Investigation 55:3, pages 229-251.
Crossref
Crossref
Tsutomu Takeuchi, Ryo Nakajima, Shuichi Komatsu, Kiyotaka Yamazaki, Tomohiro Nakamura, Naoki Agata, Ataru Igarashi, Toshiro Tango & Yoshiya Tanaka. (2017) Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. Advances in Therapy 34:3, pages 686-702.
Crossref
Crossref
Kyoko Honne, Ingileif Hallgr?msd?ttir, Chunsen Wu, Ronnie Sebro, Nicholas P. Jewell, Takeo Sakurai, Masahiro Iwamoto, Seiji Minota & Damini Jawaheer. (2016) A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis. Arthritis Research & Therapy 18:1.
Crossref
Crossref
Takao Koike, Masayoshi Harigai, Naoki Ishiguro, Shigeko Inokuma, Syuji Takei, Tsutomu Takeuchi, Hisashi Yamanaka, Yoshinari Takasaki, Tsuneyo Mimori, Katsutoshi Hiramatsu, Shuichi Komatsu & Yoshiya Tanaka. (2015) Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). Rheumatology and Therapy 3:1, pages 129-141.
Crossref
Crossref
Takahiko Sugihara & Masayoshi Harigai. (2016) Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs & Aging 33:2, pages 97-107.
Crossref
Crossref
Jeffrey R. Curtis, Khaled Sarsour, Pavel Napalkov, Laurie A. Costa & Kathy L. Schulman. (2015) Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Research & Therapy 17:1.
Crossref
Crossref
Kundan Iqbal & Clive Kelly. (2015) Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Therapeutic Advances in Musculoskeletal Disease 7:6, pages 247-267.
Crossref
Crossref
Takahiko Sugihara, Tatsuro Ishizaki, Tadashi Hosoya, Shoko Iga, Waka Yokoyama, Fumio Hirano, Nobuyuki Miyasaka & Masayoshi Harigai. (2015) Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). Rheumatology 54:5, pages 798-807.
Crossref
Crossref
Shunsuke Mori. (2015) Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 9s1, pages CCRPM.S23288.
Crossref
Crossref
Shunsuke MoriMineharu Sugimoto. (2015)
Pneumocystis Jirovecii
Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations
. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 9s1, pages CCRPM.S23286.
Crossref
Crossref
Kimimasa Nakabayashi, Masachika Fujiwara, Masato Nose, Ryota Matsuki, Yasuo Ohkura, Hiroshi Kamma, Masanori Sugiyama & Ayumi Sumiishi. (2015) Perforated Meckel's Diverticulitis and an Ileal Ulcer in Rheumatoid Arthritis:. The KITAKANTO Medical Journal The Kitakanto Medical Journal 65:1, pages 61-68.
Crossref
Crossref
Koei Oh, Satoshi Ito, Megumi Unno, Daisuke Kobayashi, Chinatsu Azuma, Asami Abe, Hiroshi Otani, Hajime Ishikawa, Kiyoshi Nakazono, Ichiei Narita & Akira Murasawa. (2015) The Rate of Decrease in the Disease Activity of Rheumatoid Arthritis during Treatment with Adalimumab Depends on the Dose of Methotrexate. Internal Medicine 54:9, pages 1035-1041.
Crossref
Crossref
Ryoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, Ryuji Koike, Kaori Watanabe, Hayato Yamazaki, Hayato Nagasawa, Koichi Amano, Yoshiya Tanaka, Takayuki Sumida, Atsushi Ihata, Shinsuke Yasuda, Atsuo Nakajima, Takahiko Sugihara, Naoto Tamura, Takao Fujii, Hiroaki Dobashi, Yasushi Miura, Nobuyuki Miyasaka & Masayoshi Harigai. (2014) The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. Rheumatology International 34:12, pages 1729-1736.
Crossref
Crossref
Shinya Hirabara, Nobunori Takahashi, Naoki Fukaya, Hiroyuki Miyake, Yuichiro Yabe, Atsushi Kaneko, Takayasu Ito, Takeshi Oguchi, Daihei Kida, Yuji Hirano, Takayoshi Fujibayashi, Fumiaki Sugiura, Masatoshi Hayashi, Koji Funahashi, Masahiro Hanabayashi, Shuji Asai, Naoki Ishiguro & Toshihisa Kojima. (2014) Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clinical Rheumatology 33:9, pages 1247-1254.
Crossref
Crossref
Camille Roubille & Boulos Haraoui. (2014) Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Seminars in Arthritis and Rheumatism 43:5, pages 613-626.
Crossref
Crossref
Sofia Ramiro, Cécile Gaujoux-Viala, Jackie L Nam, Josef S Smolen, Maya Buch, Laure Gossec, Désirée van der Heijde, Kevin Winthrop & Robert Landewé. (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases 73:3, pages 529-535.
Crossref
Crossref
Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Nobuyuki Miyasaka, Masaya Mukai, Tsukasa Matsubara, Shoji Uchida, Hideto Akama, Hartmut Kupper, Vipin Arora & Yoshiya Tanaka. (2014) Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Annals of the Rheumatic Diseases 73:3, pages 536-543.
Crossref
Crossref
Kenji Takahashi, Hiroshi Nakamura, Kenji Takenouchi, Norishige Iizawa, Masahito Koiwa, Akiko Sato, Yusuke Mochizuki, Hiroshi Watanabe & Shinro Takai. (2014) Serum KL-6 Elevation and Possible Pulmonary Involvement in Patients with Rheumatoid Arthritis Treated with Biological Agents. Journal of Nippon Medical School 81:6, pages 364-371.
Crossref
Crossref
Masayoshi Harigai. (2013) 8. Risk and Management of Infectious Complications in Patients with Autoimmune Diseases Treated with Biologicals. Nihon Naika Gakkai Zasshi 102:9, pages 2404-2412.
Crossref
Crossref